Skip to contentK
Kraig Biocraft Laboratories, Inc.
K
KBLBKraig Biocraft Laboratories, Inc. Q4 2017 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$70.10K$70.10Kderived+431.6% vs Q4 2016 Net Income-$298.83K-$298.83KderivedN/M vs Q4 2016 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Kraig Biocraft Laboratories, Inc. · CIK 1413119 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$251,068N/M Operating Cash Flowderived-$79,273N/M Free Cash Flowderived-$86,270N/M Margins · derivedOperating margin-358.2%+6299.6 pt vs Q4 2016
Net margin-426.3%+6493.1 pt vs Q4 2016
ended Dec 31, 2017 · filed Mar 23, 2018 · 82 d after period end